OPKO Health (OPK) news
Recent news
Opko Health issues $125M notes secured by Mazdutide royalties
Opko Health Issues $125M Notes Secured by Mazdutide Royalties Opko Health, Inc. (NASDAQ: OPK) has issued $125 million in secured notes backed by royalties from Eli Lilly’s Mazdutide, a GLP-1-based obesity drug commercialized in China by Innovent Biologics. The transaction is part of the company’s…
AInvest Wire · Aug 13, 2026Opko Health gains 12% after boosting year revenue outlook
Opko Health reported second-quarter revenue of $163.5 million, exceeding the estimated $131.2 million, and subsequently boosted its full-year revenue outlook, leading to a 12% stock gain; the information is based on public financial disclosures as reported by relevant market news sources.
AInvest Wire · Jul 27, 2026Opko Health 2Q revenue $163.5M, estimate $131.2M
AInvest Wire · Jul 27, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.